

## Product Information

**SILu™Prot MAPK1,**  
**Mitogen activated protein kinase 1, human**  
**recombinant, expressed in HEK cells**  
**SIL MS Protein Standard, <sup>13</sup>C- and <sup>15</sup>N-labeled**

Catalog Number **MSST0009**  
Storage Temperature **-20 °C**

Synonym: Extracellular signal-regulated kinase 2 (Erk2)

### Product Description

SILu™Prot MAPK1 is a recombinant, stable isotope-labeled human MAPK1 which incorporates [<sup>13</sup>C<sub>6</sub>, <sup>15</sup>N<sub>4</sub>]-Arginine and [<sup>13</sup>C<sub>6</sub>, <sup>15</sup>N<sub>2</sub>]-Lysine. Expressed in human 293 cells, it is designed to be used as an internal standard for bioanalysis of MAPK1 in mass spectrometry. SILu™Prot MAPK1 is a monomer of 380 amino acids (including N-terminal polyhistidine and FLAG® tags), with a calculated molecular mass of 44.2 kDa.

MAPK1 is a cytoplasmic protein that following activation is capable of translocating to the nucleus where it phosphorylates and regulates nuclear proteins (e.g., Elk-1, c-Myc, c-Jun, c-Fos, and C/EBP beta).<sup>1</sup> It is a protein serine/threonine kinase that is a member of the extracellular signal-regulated kinases (ERKs) which are activated in response to numerous growth factors and cytokines.<sup>2</sup> Aberrations in the RAS-MAPK complex (of which MAPK1 is a downstream effector) are implicated in several human cancers, and this renders the pathway an attractive therapeutic target.<sup>3</sup>

Each vial contains 10–13 µg of SILu™Prot MAPK1 standard, in a 0.1 mg/mL solution of 20 mM sodium phosphate, pH 8.0, 1 M NaCl, 1 mM EDTA, and 25% glycerol. Vial content was determined by the Bradford method using BSA as a calibrator. The correction factor from the Bradford method to Amino Acid Analysis is 90% for this protein.

Identity: Confirmed by peptide mapping

Purity: ≥95% (SDS-PAGE)

Heavy amino acid incorporation efficiency: ≥98% (MS)

UniProt: P28482

### Sequence Information

The N-terminal polyhistidine and FLAG tags are italicized.

*MDYKDDDDKGHHHHHHHHGGQAAAAAAGAGPEMV*  
*RGQVFDVGPRTNLSYIGEGAYGMVCSAYDNVNKVR*  
*VAIKKISPFHQTYCQRTLREIKILLRFRHENIIGINDIIR*  
*APTIEQMKDVYIVQDLMETDLYKLLKTQHLSDHICYF*  
*LYQILRGLKYIHSANVLHRDLKPSNLLLNTTCDLKICDF*  
*GLARVADPDHDHTGFLTEYVATRWYRAPEIMLNSKG*  
*YTKSIDIWSVGCILAEMLSNRPIFPKGHYLDQLNHILGI*  
*LGSPSQEDLNCIINLKARNYLLSLPHKNKVPWNRLFP*  
*NADSKALDLLDKMLTFNPHKRIEVEQALHPYLEQYY*  
*DPSDEPIAEAPFKFDMELDDLPEKELKELIFEETARFQ*  
*PGYRS*

### Precautions and Disclaimer

This product is for R&D use only, not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

### Storage/Stability

Store the product at -20 °C. The product is stable for at least 2 years as supplied. After initial thawing it is recommended to store the protein in working aliquots at -20 °C.

## References

1. Levin-Salomon, V. et al., Isolation of Intrinsically Active (MEK-independent) Variants of the ERK Family of Mitogen-activated Protein (MAP) Kinases. *J. Biol. Chem.*, **283**, 34500-34510 (2008).
2. Boulton, T.G. et al., Purification and properties of extracellular signal-regulated kinase 1, and insulin-stimulated microtubule-associated protein 2 kinase. *Biochemistry*, **30**, 278-286 (1991).
3. Santarpia, L. et al., Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. *Expert Opin. Ther. Targets*, **16(1)**, 103-119 (2012).

FLAG is a registered trademark and SILu is a trademark of Sigma-Aldrich Co. LLC.

## Legal Information

Sold under license from DuPont, U.S. Patent No. 7,396,688.

This product is licensed under U.S. Patent No. 7,396,688 and foreign counterparts from E. I. du Pont de Nemours and Company. The purchase of this product conveys to the buyer the nontransferable right to use the purchased amount of the product for research and development only, including services for a third party for consideration. The buyer cannot sell or otherwise transfer this product, its components or materials made using this product or its components to a third party. Information about licenses for excluded uses is available from: E. I. du Pont de Nemours and Company; Attn: Associate Director, Commercial Development; DuPont Experimental Station E268; 200 Powdermill Rd.; Wilmington, DE 19803; 1-877-881-9787 (voice), 1-302-695-1437 (fax), [licensing@dupont.com](mailto:licensing@dupont.com).

AA,NA,AI,MAM,KR 08/16-1